Current and emerging therapeutic targets for IBD

MF Neurath - Nature Reviews Gastroenterology & Hepatology, 2017 - nature.com
Various therapeutic advances have led to a paradigm shift in the clinical management of
patients with IBD. The introduction of immunosuppressive (such as azathioprine) and …

IBD disease-modifying therapies: insights from emerging therapeutics

NG Kotla, Y Rochev - Trends in Molecular Medicine, 2023 - cell.com
Inflammatory bowel disease (IBD) pathogenesis is associated with gut mucosal
inflammation, epithelial damage, and dysbiosis leading to a dysregulated gut mucosal …

Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation

D Li, Y Feng, M Tian, J Ji, X Hu, F Chen - Microbiome, 2021 - Springer
Background Ulcerative colitis is a type of chronic inflammatory bowel disease closely
associated with gut microbiota dysbiosis and intestinal homeostasis dysregulation. Barley …

Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial

P Moayyedi, MG Surette, PT Kim, J Libertucci, M Wolfe… - Gastroenterology, 2015 - Elsevier
Background & Aims Ulcerative colitis (UC) is difficult to treat, and standard therapy does not
always induce remission. Fecal microbiota transplantation (FMT) is an alternative approach …

Vedolizumab as induction and maintenance therapy for ulcerative colitis

BG Feagan, P Rutgeerts, BE Sands… - … England Journal of …, 2013 - Mass Medical Soc
Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized …

Bilirubin nanomedicine rescues intestinal barrier destruction and restores mucosal immunity in colitis

AT Rahman, J Shin, CH Whang, W Jung, D Yoo… - ACS …, 2023 - ACS Publications
Inflammatory bowel disease (IBD) manifests as intestinal barrier destruction, mucosal
immunity dysregulation, and disrupted gut microbiome homeostasis. Conventional anti …

Reaching the end-game for GWAS: machine learning approaches for the prioritization of complex disease loci

HL Nicholls, CR John, DS Watson, PB Munroe… - Frontiers in …, 2020 - frontiersin.org
Genome-wide association studies (GWAS) have revealed thousands of genetic loci that
underpin the complex biology of many human traits. However, the strength of GWAS–the …

TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

K Gerlach, YY Hwang, A Nikolaev, R Atreya… - Nature …, 2014 - nature.com
The molecular checkpoints that drive inflammatory bowel diseases are incompletely
understood. Here we found more T cells expressing the transcription factor PU. 1 and …

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

R Atreya, H Neumann, C Neufert, MJ Waldner… - Nature medicine, 2014 - nature.com
As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's
disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for …

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically

TL Putoczki, S Thiem, A Loving, RA Busuttil, NJ Wilson… - Cancer cell, 2013 - cell.com
Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives
many of the cancer" hallmarks" through downstream activation of the gp130/STAT3 …